serval:BIB_D59B3440A204
Classification of current anticancer immunotherapies.
25537519
000348038000001
Galluzzi
L.
author
Vacchelli
E.
author
Bravo-San Pedro
J.M.
author
Buqué
A.
author
Senovilla
L.
author
Baracco
E.E.
author
Bloy
N.
author
Castoldi
F.
author
Abastado
J.P.
author
Agostinis
P.
author
Apte
R.N.
author
Aranda
F.
author
Ayyoub
M.
author
Beckhove
P.
author
Blay
J.Y.
author
Bracci
L.
author
Caignard
A.
author
Castelli
C.
author
Cavallo
F.
author
Celis
E.
author
Cerundolo
V.
author
Clayton
A.
author
Colombo
M.P.
author
Coussens
L.
author
Dhodapkar
M.V.
author
Eggermont
A.M.
author
Fearon
D.T.
author
Fridman
W.H.
author
Fučíková
J.
author
Gabrilovich
D.I.
author
Galon
J.
author
Garg
A.
author
Ghiringhelli
F.
author
Giaccone
G.
author
Gilboa
E.
author
Gnjatic
S.
author
Hoos
A.
author
Hosmalin
A.
author
Jäger
D.
author
Kalinski
P.
author
Kärre
K.
author
Kepp
O.
author
Kiessling
R.
author
Kirkwood
J.M.
author
Klein
E.
author
Knuth
A.
author
Lewis
C.E.
author
Liblau
R.
author
Lotze
M.T.
author
Lugli
E.
author
Mach
J.P.
author
Mattei
F.
author
Mavilio
D.
author
Melero
I.
author
Melief
C.J.
author
Mittendorf
E.A.
author
Moretta
L.
author
Odunsi
A.
author
Okada
H.
author
Palucka
A.K.
author
Peter
M.E.
author
Pienta
K.J.
author
Porgador
A.
author
Prendergast
G.C.
author
Rabinovich
G.A.
author
Restifo
N.P.
author
Rizvi
N.
author
Sautès-Fridman
C.
author
Schreiber
H.
author
Seliger
B.
author
Shiku
H.
author
Silva-Santos
B.
author
Smyth
M.J.
author
Speiser
D.E.
author
Spisek
R.
author
Srivastava
P.K.
author
Talmadge
J.E.
author
Tartour
E.
author
Van Der Burg
S.H.
author
Van Den Eynde
B.J.
author
Vile
R.
author
Wagner
H.
author
Weber
J.S.
author
Whiteside
T.L.
author
Wolchok
J.D.
author
Zitvogel
L.
author
Zou
W.
author
Kroemer
G.
author
article
review
2014
Oncotarget
1949-2553
1949-2553
journal
5
24
12472-12508
During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into "passive" and "active" based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches.
adoptive cell transfer
checkpoint blockers
dendritic cell-based interventions
DNA-based vaccines
immunostimulatory cytokines
peptide-based vaccines
oncolytic viruses
Toll-like receptor agonists
eng
60_published
Publication types: Journal Article Publication Status: ppublish
University of Lausanne
mailto:serval_help@unil.ch
http://www.unil.ch/serval
http://serval.unil.ch/disclaimer
https://serval.unil.ch/notice/serval:BIB_D59B3440A204